Episode # 19 • 06 Jan 2026
Intravenous Antiplatelet Therapy in Acute Coronary Syndrome
Preventing problems before they aggregate, P2Y12 inhibitor style! In this episode of the BackTable Cardiology Podcast, interventional cardiologist Dr. Hayder Hashim from MedStar Washington Hospital Center joins host Dr. Hady Lichaa for practical insights and key takeaways on antiplatelet use in the setting of acute coronary syndrome (ACS).
This podcast is supported by an educational grant from Cheisi.
Timestamps
00:00 - Introduction
03:31 - Intravenous Antiplatelet Therapies Overview
06:01 - The Importance of IV P2Y12 Inhibitors
09:15 - Guidelines and Usage of GP IIb/IIIa Inhibitors
11:30 - Advantages of IV P2Y12 Inhibitors in Clinical Practice
14:32 - Practical Applications and Case Studies
24:42 - Cost Effectiveness, Hospital Administration, Financial Implications
28:20 - Contraindications and Practical Considerations
30:09 - Loading and Infusion Protocols
34:58 - Bridging for Surgery
39:48 - Anticoagulation and Heparin Goals
48:55 - Future of IV Antiplatelet Therapy
50:44 - Conclusion
Resources
- Association of 2B3A inhibition with new antiplatelet regimens in the setting of acute coronary syndromes: a meta-analysis of randomized controlled trials
- Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events - CHAMPION PHOENIX
- Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial
- Abstract 4370674: Cangrelor Versus Oral P2Y12 Inhibitors During PCI in Cardiogenic Shock and Cardiac Arrest: A Systematic Review and Meta-analysis
- Dr. Hayder Hashim
- Dr. Hady Lichaa
You may also like
More about this episode
Dr. Hashim talks through the use of intravenous antiplatelet therapies, specifically cangrelor, for managing acute coronary syndrome. Their discussion explores the pharmacokinetics, clinical advantages, and potential future applications of IV P2Y12 inhibitors. Dr. Hashim shares his wealth of experience in antiplatelet case studies and shares best practices when transitioning patients from IV to oral antiplatelet therapies. The conversation focuses on enhancing patient outcomes, minimizing complications, and lessons learned from different clinical scenarios.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.